Columns The MS Wire - A Column by Ed Tobias MS News Notes: aHSCT, Iron Rim Lesions, Smell Test, Electrical Brain Stimulation MS News Notes: aHSCT, Iron Rim Lesions, Smell Test, Electrical Brain Stimulation Columnist Ed Tobias comments on the week's top MS news by Ed Tobias | October 10, 2022 Share this article: Share article via email Copy article link The following multiple sclerosis (MS) news stories caught my eye last week: Stem cell transplant and nerve fiber damage This small study of 43 people with relapsing-remitting multiple sclerosisĀ who underwent autologous hematopoietic stem cell transplant (aHSCT) in Sweden reports that their disability during the period of study ā about seven years, plus a four-year follow-up ā was generally stable or their impairment was reduced. To me, this is additional evidence that we should make aHSCT available to more people with MS. Autologous hematopoietic stem cell transplant (aHSCT) reduces markers of nerve fiber and myelin damage in people with relapsing-remitting MS (RRMS), according to a small study done in Sweden. āWe investigated if therapeutic intervention with aHSCT could halt the injurious process leading to tissue damage in MS,ā researchers wrote. āOur main finding is that a majority of patients reach that goal with time, regardless of subsequent disease activity.ā Recommended Reading September 19, 2022 News by Marisa Wexler, MS Gut Bacteria Are Altered in MS, Linked to Disease Progression Iron rim lesions and disease severity Some people call iron rim lesions “smouldering MS.” The lesions are active, but their growth is slow. It’s been thought for some time that they indicate a more aggressive MS course. But this is the first study that I know of to suggest that tracking these lesions with MRIs could lead to a more accurate MS prognosis. The presence of iron rim lesions, which are regions of chronic inflammation seen on MRI scans, may be linked to a more severe disease course in people with multiple sclerosis, according to a recent study. The findings suggest the presence and number of iron rim lesions could serve āas an imaging biomarker for disease severity, which could be easily implemented in clinical practice,ā researchers wrote. Smell test My wife smells everything, but I smell very little. She thinks I have no nose, while I think hers is oversensitive. We’re probably both right. Maybe now I can blame my MS for having no nose. Evaluating a personās sense of smell may help monitor disease progression in people with MS, according to a recent study. Almost a third of MS patients studied showed signs of smell loss in clinical evaluations and the degree of impairment correlated with clinical measures of disease, such as disability, MS duration, and cognitive performance. Electrical brain stimulation Easing MS spasticity with direct electrical stimulation of the brain is an interesting concept, but it’s just that ā a concept. The subjects of this small study in Egypt underwent five 20-minute electrical brain stimulation treatments that resulted in improvement in some, but not all, of three test measures of spasticity. There also was no indication of how long the improvement lasted. I expect I’ll be sticking to my baclofen prescription to treat my leg spasticity for some time to come. Electrical stimulation of the brain through electrodes placed on the scalp may ease some measures of spasticity for people with relapsing-remitting MS, according to results from a small clinical trial. Using this novel route of brain stimulation was shown to impact muscle contractions in patients with spasticity in at least one leg. The procedure, called transcranial direct current stimulation (tDCS), āis non-invasive, easily applicable and could [reduce] spasticity in MS,ā the researchers wrote. Note:Ā Multiple Sclerosis News TodayĀ is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofĀ Multiple Sclerosis News TodayĀ or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. Heās also the author of āThe Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.ā Ed and his wife split their time between the Washington, D.C. suburbs and Floridaās Gulf Coast, trying to follow the sun. Tags autologous hematopoietic stem cell transplant, MS News Comments Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
May 7, 2024 News by Margarida Maia, PhD Wayne State professor wins grant to study oligodendrocytes in MS
May 6, 2024 News by Marisa Wexler, MS Nearly $650k awarded to advance potential remyelination drug IFB-048